Effects of nebivolol on platelet activation in hypertensive patients: A comparative study with metoprolol
International Journal of Cardiology, cilt.116, sa.2, ss.206-211, 2007 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 116 Sayı: 2
- Basım Tarihi: 2007
- Doi Numarası: 10.1016/j.ijcard.2006.03.046
- Dergi Adı: International Journal of Cardiology
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.206-211
- Anahtar Kelimeler: hypertension, nebivolol, metoprolol, platelet activation
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objectives: We evaluated the effects of nebivolol on platelet activation in hypertensive patients by measuring mean platelet volume (MPV) and plasma soluble P-selectin (sP-sel) levels and compared with those of the patients taking metoprolol. Materials and methods: Eighty newly diagnosed hypertensive patients in grade 1 hypertension were enrolled in this prospective, blinded randomized study. Seventy two patients completed the study. After baseline assessment, each patient was randomly allocated to 5 mg daily dose of nebivolol (n = 37, 20 male) or 100 mg daily dose of metoprolol (n = 35, 18 male) and treated for 6 months. Blood pressure, heart rate, lipid profile, plasma glucose, sP-selectin levels, platelet counts and MPV were measured before and after treatment. Results: At the end of 6 months, nebivolol significantly decreased MPV and plasma sP-selectin levels (7.59 ± 0.78 fl vs. 7.42 ± 0.74 fl, p < 0.001; 1.29 ± 0.46 ng/ml vs. 1.21 ± 0.36 ng/ml, p = 0.002, respectively) compared to those of pretreatment. Although pretreatment sP-selectin levels of the two groups were similar, posttreatment plasma sP-selectin levels were significantly reduced with nebivolol compared with those of metoprolol group (1.21 ± 0.36 ng/ml vs. 1.46 ± 0.30 ng/ml, p = 0.008). In contrast, metoprolol treatment did not cause any significant change in platelet activation parameters after treatment. Conclusion: Beneficial effects of nebivolol on platelet activation were more potent than those of metoprolol. We consider that decreased platelet activation with nebivolol might play a role to reduce thrombotic risk in hypertensive patients. © 2006 Elsevier Ireland Ltd. All rights reserved.